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submissions. BCVA (Best Corrected Visual Acuity) scores were available for limited 
number of East Asian patients (N= 35) from a phase III, 12-month, randomized, 
double-masked, multicenter, active-controlled study (RADIANCE). To populate a 
transition probability matrix with 8 health states based on BCVA scores, a statisti-
cal model was proposed to simulate a larger hypothetical patient cohort. A mixed-
effect model was fitted on the observed BCVA scores with baseline BCVA score as 
covariate, patients as random effect and an autoregressive AR(1) error correlation 
structure amongst the repeated observations. This model was used to simulate a 
patient cohort of 35,000. Transition probabilities were estimated using traditional 
division by row sum method. Several simulations were run to confirm consistency 
of results. Results: From baseline to month 3, percentage of patients with BCVA 
≥ 20 letters gain was 22.45% in observed data vs 22.49% in simulated data, and 
percentage of patients with BCVA ≥ 20 letters loss was 0.008% in observed data 
vs 0.009% in simulated data. BCVA change from baseline to month 3 in simulated 
data (mean= 13.3, SD= 8.3) was verified with that of the observed data (mean= 13.3, 
SD= 8.8). ConClusions: Transition probability estimation by simulation from a 
fitted statistical model can overcome the challenges posed by small patient cohorts 
and multiple state transitions.
MO3
ExtrapOlatiOn Of trial-BasEd survival CurvEs using ExtErnal 
infOrMatiOn
Guyot P.1, Welton N.J.2, Beasley M.3, Ades A.E.2
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objeCtives: In cost-effectiveness analysis (CEA), mean survival difference (QALY-
adjusted) over a lifetime horizon is required. Parametric models are necessary to 
extrapolate survival outcomes beyond the Randomized Controlled Trial (RCT) period. 
However, mean survival is very sensitive to the assumed model and different mean 
survival times may result from models fitting similarly well to the RCT data. We 
investigate the idea that other sources of information, external to the trial data, 
could be used to inform model choice and estimation. Methods: We explored 
various survival models and we show how external information can be used to 
put constraints on spline-based survival models. We illustrate with a Technology 
Appraisal (TA) of head and neck cancer where RCT evidence had 5 year follow up. 
A US cancer database (SEER), general population data and expert opinion were 
used to impose constraints on overall survival, conditional survival, and hazard 
ratio. RCT and external data were fitted simultaneously within a Bayesian frame-
work. Results: Standard survival time distributions were insufficiently flexible 
to simultaneously fit both the RCT data and general population constraints. Spline 
models were sufficiently flexible, although there were difficulties choosing initial 
values. A good fit to all sources of internal and external evidence was achieved 
within one integrated model using splines on the log hazard. Cetuximab in addi-
tion to radiotherapy improves the expected survival by 4.7 months [95% CrL: 0.4; 
9.1] compared to radiotherapy alone. ConClusions: The method enabled us to 
estimate models consistent with all evidence. Clinical knowledge is essential to 
guide the interpretation of the external data sources. The method could be used 
to analyze other RCTs on other cancers and with other treatments. Other flexible 
models than splines could be investigated.
MO4
EstiMating survival data frOM puBlishEd Kaplan-MEiEr CurvEs: a 
COMparisOn Of MEthOds
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objeCtives: Health technology assessment of treatments often requires estimates 
of their survival curves. Individual patient data (IPD) are often unavailable and the 
survival curves are usually calculated by fitting a nonlinear least squares (NLS) 
model directly to Kaplan Meier plots provided in the published literature. This 
method does not account for the uncertainty associated with the Kaplan Meier 
curve and can lead to biased estimates. Although the IPD are often missing, the 
Kaplan Meier curve itself can be digitised and used to approximate what the origi-
nal IPD could have been. Methods: We simulated trial IPD data from different 
survival distributions in order to assess the accuracy of the IPD reconstruction 
methods. The assessment of accuracy is made at multiple stages and ultimately 
the effects on the incremental cost effectiveness ratio (ICER) estimates are com-
pared. To do so, a simple cost-effectiveness model was developed, assuming two 
health states (alive and dead), and assigning costs (£1,000 per month plus drug 
costs) and a utility score (0.70) to generate ICERs. Two additional methods to curve 
fitting are compared against the NLS approach – those suggested by Guyot (G), and 
by Hoyle & Henley (HH). Results: We find that the methods differ in accuracy at 
each of the following two stages; (a) model selection via the AIC and secondly (b) 
survival model parameter estimation. When an underlying Weibull function was 
assumed, the ‘true’ ICER should be £28,924, compared against £31,182 £33,449 and 
£31,650 for the NLS, HH and G methods respectively. When an underlying loglogistic 
function was assumed, the NLS, HH and GG methods produced ICERs of £26,507, 
£25,559 and £25,857, compared to a ‘true’ ICER of £25,779. ConClusions: These 
findings suggest that inherent biases may be apparent in each of the approaches, 
and these may manifest themselves differently, depending upon the ‘true’ shape 
of the underlying data.
Qaly-rElatEd studiEs
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ECOnOMiC Orphans? thE prEvalEnCE Of Child-spECifiC utilitiEs in niCE 
appraisals fOr paEdiatriC indiCatiOns
Montgomery S., Hassan M., Kusel J.
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be viewed as biases or an expression of true preferences is a matter for further 
discussion.
hC4
undErstanding thE payEr dilEMMa with BiOsiMilar MaBs: striKing 
thE right BalanCE BEtwEEn BudgEt nEEds and patiEnt OutCOMEs
Vidal Pinheiro A., Ziai Buetas A., Storer M.
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objeCtives: The first infliximab biosimilars reached the EU in September 2013, 
representing the first biosimilar monoclonal antibodies (mAbs) to obtain EMA 
approval. Although commercialization in the major European markets will only 
start in February 2015, payers in Nordic and Eastern European countries have already 
faced the dilemma of striking the balance between potential savings accrued from 
use of less expensive infliximab biosimilars and demands for robust proof of clinical 
efficacy and safety. This work identifies payers’ evidence expectations, their reli-
ance on regulators’ decisions and how potential savings can influence access and 
recommendations to target patient populations. Methods: Exploratory qualita-
tive primary research with payers (N= 12) from France, Italy, Spain, UK, Germany 
and Netherlands. Collection of data about the current and future attitudes towards 
biosimilar health technology assessments at the national and, if applicable, local 
levels will be conducted, as well as perceived price and access trade-offs. Results: 
(1) Payers will mainly defer to the EMA the decision on acceptability of biosimilar 
indication extrapolation (indications where biosimilars do not have direct clinical 
trial data); (2) It is understood that mAb biosimilar clinical development is more 
onerous and costly than small molecule generics, thus payers do not expect the 
same magnitude of discounts offered vs. originator; (3) Although eager to obtain 
savings from broad patient populations, payers will not implement pharmacy-level 
substitution or enforce biosimilar use in originator-experienced patients; (4) Use in 
naïve patients will be recommended in most markets. ConClusions: Across the 
EU5, payers acknowledge physicians’ concerns over long term safety and efficacy 
of biosimilars. Nonetheless, they will rely on the regulators evaluations and expert 
panels to justify implementing recommendations, and in some markets, restrict 
formularies based exclusively on cost. Moreover, they have conservative discount 
expectations at launch, with the long-term aim of incentivizing further competition 
from other biosimilar manufacturers.
rEsEarCh On MEthOds – Modeling studies
MO1
Quasi-MOntE CarlO siMulatiOn and varianCE rEduCtiOn tEChniQuEs 
suBstantially rEduCE COMputatiOnal rEQuirEMEnts Of patiEnt-lEvEl 
siMulatiOn MOdEls: an appliCatiOn tO a disCrEtE EvEnt siMulatiOn 
MOdEl
Treur M.1, Postma M.2
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objeCtives: Patient-level simulation models provide increased flexibility to over-
come the limitations of cohort-based approaches in health-economic analysis. 
However, computational requirements of reaching convergence is a notorious 
barrier. The objective was to assess the impact of using quasi-monte carlo simu-
lation (QMCS) and variance reduction techniques (VRTs) on computational require-
ments. Methods: A recently published discrete event simulation model assessing 
the cost-effectiveness of an adjunctive antipsychotic treatment for depression was 
used. The following VRTs were implemented: antithetic variables, common random 
numbers (CRN) and the combination (Anti_CRN). In addition, QMCS was conducted 
using the Sobol low discrepancy sequence. The minimal number of patients required 
to reach equal precision as the reference situation of 1,000,000 simple monte carlo 
simulations (MCS) was recorded. Precision was defined by the standard error (SE) 
of the incremental net monetary benefit (INMB) at a willingness to pay of € 20,000 
per quality adjusted life year gained. VRT simulations were replicated 100 times. 
INMB estimates were compared with the reference situation using mean squared 
error (MSE), mean absolute error (MAE) and percentage of under- and overesti-
mations. Results: Reference INMB (SE) was € 1,413 (76). The average number of 
patients required to reach reference precision were 929,628, 35,692, 41,683 and 
36,803 for antithetic variables, CRN, Anti_CRN and Sobol respectively. This implied 
a computation time reduction ranging between 7% and 96% compared to simple 
MCS. MSE was 346,036, 16,314, 155,950 and 7,475 respectively. MAE was 588, 105, 
387 and 86 respectively. Antithetic variables and Anti_CRN structurally underes-
timated INMB (99% and 100%). CRN marginally overestimated INMB in 76 replica-
tions. ConClusions: QMCS and VRT reduce computational requirements in terms 
of simulated patients and computational time up to 96%, enhancing the practical 
feasibility of patient-level simulation models. This particularly applies to Sobol and 
CRN. Antithetic variables should be used with caution and its structural bias war-
rants further research.
MO2
transitiOn prOBaBility EstiMatiOn using rEpEatEd saMpling frOM a 
fittEd MixEd MOdEl
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objeCtives: Markov model is one of the most used decision analytic models in 
health care. Transitions between health states in a Markov model is driven by tran-
sition probability matrix. When the number of patients and observed transitions 
are limited, transition probability estimation becomes challenging. The objective 
of this exercise is to demonstrate how transition probabilities can be estimated by 
simulating data from a statistical model fitted to patient-level data. Methods: 
An economic model for ranibizumab in mCNV secondary to pathological myopia 
(submitted to NICE in June 2013) was adapted for forthcoming Asian reimbursement 
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€ 42,600/QALY for payers. ConClusions: All the estimated ICER values were higher 
than the thresholds usually described in the literature (€ 20,000-30,000/QALY), with 
relevant differences among the groups. In both scenarios, payers were less prone 
to pay for therapeutic improvements compared to the rest of the participants. On 
the other hand, oncologists were the ones that most valued gains in survival for 
a new treatment while patients assigned a higher value for money to a treatment 
that enhanced the quality of life.
Qa4
rEiMBursEMEnt dECisiOns fOr pharMaCEutiCals in swEdEn: thE 
iMpaCt Of COst-EffECtivEnEss and disEasE sEvErity
Nilsson F.O.L.1, Svensson M.2, Arnberg K.1
1Dental and Pharmaceutical Benefits Agency, Stockholm, Sweden, 2Örebro University, Örebro, 
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objeCtives: The purpose of this study is to evaluate the impact of cost-effec-
tiveness and disease severity on the drug reimbursement decisions made by the 
reimbursement agency TLV in Sweden. Methods: Cost-effectiveness is measured 
through the continuous variable cost per QALY, while disease severity is meas-
ured by a dichotomous variable indicating high- or not high disease severity. We 
analyze all reimbursement decisions from 2005 through 2011 where there is data 
available on cost per QALY and disease severity. Logistic regressions are used to 
evaluate the impact of cost-effectiveness and disease severity on the drug reim-
bursement decisions. Results: There are 102 decisions with the required data 
available, 86 where reimbursement was granted and 16 where reimbursement was 
denied. The median cost per QALY for the drugs that were granted reimbursement 
was 39 000 euro (9sek/euro), ranging from a negative cost per QALY (better and 
cheaper) to 136 000 euro. The median cost per QALY for the drugs that were denied 
reimbursement was 111 000 euro, ranging from 78 000 euro to 1 111 000 euro. The 
results from the logistic regression analysis show that both the cost per QALY and 
the level of disease severity are statistically significantly related to the probability 
of a drug being granted reimbursement. When the cost per QALY exceeds 56 000 
euro for non-severe diseases, and 92 000 euro for severe diseases, the probability 
that reimbursement is denied is higher than the probability that reimbursement 
is granted. ConClusions: In Sweden, it is sometimes stated as a rule of thumb 
that 55 000 euro per QALY is a threshold for cost-effective interventions. Our model 
shows that at this cost-effectiveness ratio, the probability of a new drug becoming 
reimbursed is 91 % or 98 %, depending on disease severity.
rEsEarCh pOdiuM prEsEntatiOns – sEssiOn ii
CardiOvasCular disEasE rEsEarCh studiEs
Cv1
thE iMpOrtanCE Of trEatMEnt ClassifiCatiOns that aCCOunt fOr 
COnCOMitant trEatMEnts in thE COntExt Of a nEtwOrK MEta-
analysis COMparing pharMaCOlOgiCal trEatMEnts fOr ChrOniC 
hEart failurE
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objeCtives: The aim of the study was to assess the comparative efficacy of rec-
ommended treatment for chronic heart failure with reduced ejection fraction in 
terms of all-cause mortality based on a network met-analysis (NMA) of randomized 
controlled trials (RCTs) and to explore the impact of alternative treatment classifi-
cations depending on concomitant treatments. Methods: A systematic literature 
search identified 56 relevant RCTs (1980-2013) that reported mortality data that 
were synthesized using a Bayesian Poisson regression NMA model. Treatments 
were classified as angiotensin converting enzyme inhibitors (ACEI), beta-blockers 
(BB), angiotensin II receptor blockers (ARB), mineralocorticoid/aldosterone receptor 
antagonists (MRA) and the Ifchannel inhibitor (IF) ivabradine. Analysis 1 classified 
treatments according to the main drugs of interest, whereas Analysis 2 defined 
treatments according to the main drugs of interest as well as the concomitant 
treatments belonging to classes of interest if more than 50% of patients were tak-
ing concomitant drugs. Results: Six regimens were compared in Analysis 1 and 
10 regimens were compared in Analysis 2. Analysis 1 resulted in the following rate 
ratios (RR) versus placebo: ACEI: 0.81 (95% Credible Interval 0.61, 0.95); BB: 0.71 (0.60, 
0.80); ARB: 0.90 (0.75, 1.02); ACEI+BB: 0.48 (0.30, 0.76). Analysis 2 resulted in the fol-
lowing RRs versus placebo: ACEI: 0.81 (0.68, 0.95); BB: 0.57 (0.35, 0.87); ARB: 0.81 (0.61, 
1.01); ACEI+BB: 0.61 (0.54, 0.68). The treatments that are expected to be most effica-
cious depended on the treatment classification: Analysis 1 supported ACEI+BB and 
BB, whereas Analysis 2 supported ACEI+BB+MRA+IF and ACEI+BB+MRA [RR: 0.44 
(0.34, 0.58) and 0.48 (0.38, 0.60), respectively]. ConClusions: Combination treat-
ments were likely to be more efficacious than monotherapy and adding a class to a 
regimen was likely to make it more efficacious regardless of the approach. However, 
treatment classifications affect the results and interpretation. The approach that 
accounts for concomitant treatments is preferred.
Cv2
wOrK prOduCtivity lOss and indirECt COsts assOCiatEd with nEw 
CardiOvasCular EvEnts in high-risK patiEnts with hypErlipidEMia - 
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objeCtives: Children have been termed “therapeutic orphans” due to the paucity 
of age-specific therapeutic data. Here we review the extent to which utility data 
derived from under-18s were used to inform National Institute for Health and Care 
Excellence (NICE) Technology Appraisals (TAs) providing cost-effectiveness guid-
ance in paediatric indications, in line with the NICE reference case. Methods: 
All 311 published TAs up to April 2014 were initially sifted to identify therapeu-
tic recommendations for children. Identified TAs were reviewed to determine if a 
cost-utility analysis (CUA) was performed. For each CUA, the published TA along 
with the manufacturer’s submission (single TAs) or the assessment report (multiple 
TAs) were examined to determine the origin of the utilities used. Results: Of 35 
published TAs reviewed, 27 analysed cost-per-QALY and made recommendations 
for treatment of under-18s. Of these, 17 used adult utilities, 1 of which attempted 
to adjust the adult values for children; 3 considered child and adult populations 
as one, with child-derived data used within the overall model inputs for the whole 
population, 1 of which adjusted both child and adult utilities by age. Only 6 studies 
used child-specific utilities: 1 assumed a specified change from treatment on a 
generic QoL instrument, 2 used parent-reported utilities on a generic QoL instru-
ment, 1 used parent-reported utilities mapped from a disease-specific scale and 
2 used child-reported utilities mapped from a disease-specific scale. One MTA 
contained diverging submissions, 1 adult-derived and 1 child-reported. No trends 
over time in the types of utilities used were apparent from visual examination of 
the results. ConClusions: Despite NICE’s reference case specifying that utilities 
should be measured in the population in question, children may also be termed 
“economic orphans” with the majority of cost-utility submissions applying adult-
derived utilities to paediatric indications and no trend away from this apparent 
over time.
Qa2
COst-utility Of CanCEr thErapiEs – thE ‘COst’ Of diffErEnt utility 
gEnEratiOn stratEgiEs
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objeCtives: To explore the impact of different utility measurement strategies on the 
results of a cost-effectiveness analysis, funding decisions, decision uncertainty and 
value of information. Methods: Data from a UK trial of two cancer therapies (active 
versus standard care) were analysed using NICE reference case methods. Within-trial, 
cost-utility analyses were conducted with utility based on a number of strategies: A) 
Observed EQ-5D; cancer-specific utility based on the EORTC QLQ-C30 B) the EORTC-8D 
and C) the QLQ_U; Mapping from QLQ-C30 to EQ-5D using an algorithm generated 
in D) the same cancer patient group and E) a different cancer group. Incremental 
cost-effectiveness ratios (ICERS) were calculated. Bootstrapped net benefit estimates 
allowed generation of cost-effectiveness acceptability curves (CEACs) and popula-
tion expected value of perfect information (EVPI) was calculated using incremental 
cost scenarios. Results were compared across utility strategies. Results: There were 
small but important differences observed in the incremental QALYs which ranged 
from 0.067 (EQ-5D) to 0.036 (EORTC-8D). Large differences were observed in the ICERs 
generated; for strategies A to E these were: £57,513; £106,264; £102,785; £90,049; 
£78,885. Using an incremental cost scenario of £3,000 only strategy A yielded an ICER 
< £30,000. At a QALY willingness to pay threshold (WTPT) of £20,000 there was little 
decision uncertainty. However, assuming WTPT= £50,000, the probability the active 
treatment was cost-effective ranged 0.34 (EQ-5D) to 0.025 (EORTC-8D). Using this 
threshold, the population EVPI for the strategies were: £3,597,844; £120,621; £155,858; 
£354,094; £805,847. ConClusions: Different utility sources can lead to very different 
estimates of cost-effectiveness and value of further research and change funding 
decisions. Estimates of cost-effectiveness based on mapping (even when the algo-
rithm appears to perform well) can differ substantively from those based on observed 
scores. The lowest ICERs were obtained with the EQ-5D but this may not capture 
side-effects picked up by the cancer-specific utility measures.
Qa3
dO nEw CanCEr drugs OffEr gOOd valuE fOr MOnEy? thE pErspECtivE 
Of OnCOlOgists, payErs, patiEnts, and gEnEral pOpulatiOn
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objeCtives: To analyze oncologists’, payers’, patients’, and general population´ 
views on the cost and value of new cancer treatments. Methods: An electronic 
self-administered questionnaire was developed and randomly distributed, to assess 
participants’ attitudes towards new cancer treatment outcomes and costs dur-
ing reimbursement decisions. Among the questions asked were two hypothetical 
scenarios. First, participants were asked to indicate the minimum survival benefit 
that a new treatment, that cost € 50,000 more than the standard therapy, should 
have to be funded by the Spanish National Health System (NHS). Second, partici-
pants were requested to state the highest costs to be afforded by the NHS for a 
medication increasing patient’s quality of life (QoL) twofold with no changes in 
survival. Responses were used to calculate incremental cost-effectiveness ratios 
(ICER). Results: 53 oncologists, 60 patients, 25 payers, and 50 individuals from gen-
eral population answered the questionnaire. The minimum improvement median 
in patient survival that justified the inclusion into the NHS was 5.66 months for 
oncologists, 8.16 for patients, 9.08 for general population and 10.44 for payers; 
implying different ICER for oncologists (€ 106,000/QALY), patients (€ 73,520/QALY), 
general population (€ 66,074/QALY) and payers (€ 57,471/QALY). The cost stated in 
QoL-enhancing scenario was € 33,167 for patients, € 30,200 for general population, 
€ 26,000 for oncologists and € 17,040 for payers; resulting in ICERs of € 82,917/QALY 
for patients, € 75,500/QALY for general population, € 65,000/QALY for oncologists, and 
